Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- Group of Academia-Originating Biotechs Boots Up in Japan
October 18, 2023
- Introduce Societal Value Premium for Regenerative Medicine Products: Consultant
October 17, 2023
- Chuikyo Rep Interview 2-3 - With 80% Generic Share, Now Is the Time to Revisit LLP Copay, Says Payer Rep
October 13, 2023
- Chuikyo Rep Interview 2-2 - Payer Says Drug Prices Not Only Cause of Lag/Loss, Industry Proposal Needs More Details
October 11, 2023
- JMA Survey Finds Large Gap between Actual Drug Shortage, Industry Poll
October 11, 2023
- Chuikyo Rep Interview 2-1 - As Japan Sees More Pricey Meds, Kenporen Director Wants Rethink of Health Coverage
October 10, 2023
- Eliminate Authorized Generics as They Hamper Competition: JMA
October 10, 2023
- Global CEOs Want Positive Sign from Japan, Sentiments Drive Decisions: EFPIA Chief
October 6, 2023
- Chuikyo Rep Interview 1 - JPA Vice President Warns against Rushed Dabate on Yakkasa, 2% Buffer Zone
October 4, 2023
- Japan Drug Wholesalers’ Workforce Down 3% for 2nd Year: JPWA Survey
October 3, 2023
- Generic Use Rate Reaches Record 81.7% in April-June: JGA
September 29, 2023
- Assess Evaluation Methods for Innovative Medical Products: Science Council
September 28, 2023
- Ex-MHLW CMO Calls for Reasonable Pricing of Alzheimer’s Drugs
September 27, 2023
- Shipments Restricted or Halted for 22.9% of Products in August: FPMAJ
September 25, 2023
- JPMA Embarking on Creation of One-Stop Platform for Rare Disease Trial Info
September 19, 2023
- Hiroyasu Kitagawa Named New Chief of Kyokai Kenpo
September 19, 2023
- JPMA Optimistic on New Minister’s Commitment on Boosting Innovation: Exec
September 15, 2023
- 4 Cell & Gene Therapies Represent 90% of Top 100 Bills in FY2022: Payer
September 8, 2023
- Single-Wholesaler Model Has No Merits for Hospitals: Hyogo Doctors Group
September 7, 2023
- Industry Calls for Clear Criteria for SaMD Reimbursement to Boost Predictability
September 5, 2023
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…